As per this report, the size of the Middle East & Africa Non-Invasive Prenatal Testing Market was valued at USD 0.12 Billion in 2019 and is projected to be growing at a CAGR of 4.93%, to touch USD 0.16 billion by 2024 during the forecast period 2019 - 2024.
Non-Invasive Prenatal Testing is used to identify the most common chromosome anomalies like Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), and the Patau Syndrome (Trisomy 13). The gender of a fetus can also be determined using NIPT.
Non-Invasive Prenatal Testing (NIPT) is a new category of genetic test that screens for inherited ailments and birth defects. It usually involves a simple blood screening that examines the DNA, known as cell-free DNA(cf-DNA) to precisely assess a baby’s risk for a variety of genetic disorders, such as Down syndrome.
The growth of the market is mainly driven by factors such as the introduction of newer and more advanced NIPT products and the feasibility and growing preference for non-invasive techniques over invasive ones. The market faces quite a few restraints such as low awareness among the populace about genetic disorders, very low capital investment by companies to tap untapped markets and boost the market growth. The above restraints coupled with the low clinical validity of NIPT are dimming the market growth in this region.
This research report has been segmented and sub-segmented into the following categories
Key market participants in the market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Instruments
5.1.1 Introduction
5.1.2 PCR
5.1.3 Ultrasound
5.1.4 NGS
5.1.5 Microarray
5.1.6 Y-o-Y Growth Analysis, By Instruments
5.1.7 Market Attractiveness Analysis, By Instruments
5.1.8 Market Share Analysis, By Instruments
5.2 Method
5.2.1 Introduction
5.2.2 FCMB
5.2.3 Cell-Free DNA (cf-DNA)
5.2.4 Y-o-Y Growth Analysis, By Method
5.2.5 Market Attractiveness Analysis, By Method
5.2.6 Market Share Analysis, By Method
5.3 Application
5.3.1 Introduction
5.3.2 Trisomy
5.3.3 Microdeletion
5.3.4 Genetics
5.3.5 Rh factor
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Hospital
5.4.3 Diagnostic Labs
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Instruments
6.1.3.3 By Method
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Instruments
6.1.4.3 By Method
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Instruments
6.1.5.3 By Method
6.1.5.4 By Application
6.1.5.5 By End User
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Koninklijke Philips N.V
8.3 Thermo Fisher Scientific
8.4 Hoffman-La Roche
8.5 Pacific Biosciences of California
8.6 PerkinElmer
8.7 QIAGEN N.V
8.8 Agilent Technologies
8.9 Beijing Genomics Institute
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
